RU2014105513A - Противофиброзные пептиды и их применение в способах лечения заболеваний и расстройств, характеризующихся фиброзом - Google Patents
Противофиброзные пептиды и их применение в способах лечения заболеваний и расстройств, характеризующихся фиброзом Download PDFInfo
- Publication number
- RU2014105513A RU2014105513A RU2014105513/04A RU2014105513A RU2014105513A RU 2014105513 A RU2014105513 A RU 2014105513A RU 2014105513/04 A RU2014105513/04 A RU 2014105513/04A RU 2014105513 A RU2014105513 A RU 2014105513A RU 2014105513 A RU2014105513 A RU 2014105513A
- Authority
- RU
- Russia
- Prior art keywords
- peptide
- seq
- subject
- fibrosis
- disease
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 21
- 206010016654 Fibrosis Diseases 0.000 title claims abstract 7
- 230000004761 fibrosis Effects 0.000 title claims abstract 6
- 230000002300 anti-fibrosis Effects 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 8
- 201000010099 disease Diseases 0.000 claims abstract 8
- 208000035475 disorder Diseases 0.000 claims abstract 8
- 230000037396 body weight Effects 0.000 claims abstract 4
- 208000020832 chronic kidney disease Diseases 0.000 claims abstract 4
- 239000003937 drug carrier Substances 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims abstract 2
- 206010039710 Scleroderma Diseases 0.000 claims abstract 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims abstract 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims abstract 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims abstract 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims abstract 2
- 201000008383 nephritis Diseases 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 230000009787 cardiac fibrosis Effects 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161509340P | 2011-07-19 | 2011-07-19 | |
| US61/509,340 | 2011-07-19 | ||
| US201261662337P | 2012-06-20 | 2012-06-20 | |
| US61/662,337 | 2012-06-20 | ||
| PCT/US2012/047468 WO2013013085A2 (en) | 2011-07-19 | 2012-07-19 | Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014105513A true RU2014105513A (ru) | 2015-08-27 |
Family
ID=47558730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014105513/04A RU2014105513A (ru) | 2011-07-19 | 2012-07-19 | Противофиброзные пептиды и их применение в способах лечения заболеваний и расстройств, характеризующихся фиброзом |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20140057831A1 (enExample) |
| EP (1) | EP2734220A4 (enExample) |
| JP (1) | JP2014527040A (enExample) |
| CN (2) | CN106478776A (enExample) |
| AU (1) | AU2012283924A1 (enExample) |
| BR (1) | BR112014001268A2 (enExample) |
| CA (1) | CA2842330A1 (enExample) |
| HK (1) | HK1198333A1 (enExample) |
| IL (1) | IL230510A0 (enExample) |
| RU (1) | RU2014105513A (enExample) |
| WO (1) | WO2013013085A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170232276A1 (en) * | 2014-09-30 | 2017-08-17 | Primegen Biotech, Llc | Treatment of fibrosis using deep tissue heating and stem cell therapy |
| US20160137714A1 (en) * | 2014-11-12 | 2016-05-19 | Thrasos Innovation, Inc. | Peptides with enhanced stability and their use in methods for treating diseases |
| WO2016179106A1 (en) * | 2015-05-01 | 2016-11-10 | University Of Miami | Methods and compositions for converting non-endocrine pancreatic tissue into insulin-producing cells |
| CN114181281A (zh) * | 2015-05-12 | 2022-03-15 | 加利福尼亚大学董事会 | 用于炎症和纤维化的肽治疗 |
| US10844392B2 (en) * | 2015-06-05 | 2020-11-24 | Ibio, Inc. | Materials and methods for producing endostatin fusion polypeptides in plant cells |
| WO2019133950A1 (en) * | 2017-12-30 | 2019-07-04 | The Regents Of The University Of Colorado, A Body Corporate | Smad7 for treatment and prevention of posterior capsule opacification |
| ES2906715T3 (es) * | 2018-09-06 | 2022-04-20 | Marine Essence Biosciences Corp Of Usa | Dispositivos de biomaterial para la regeneración de tejidos guiada |
| AU2019366366B2 (en) * | 2018-10-22 | 2025-09-25 | William D. Carlson | Therapeutic combinations of TDFRPs and additional agents and methods of use |
| WO2021007094A1 (en) * | 2019-07-10 | 2021-01-14 | Musc Foundation For Research Development | Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury |
| CN117106029A (zh) * | 2020-06-08 | 2023-11-24 | 深圳市图微安创科技开发有限公司 | 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途 |
| CA3212468A1 (en) * | 2021-03-16 | 2022-09-22 | William D. Carlson | Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis |
| CN113069531B (zh) * | 2021-04-09 | 2023-02-28 | 南开大学 | 一种防疤痕皮肤创伤修复用水凝胶及其制备方法 |
| CN116768974A (zh) * | 2022-03-11 | 2023-09-19 | 中山大学 | 用于预防和/或治疗肾纤维化的多肽化合物 |
| EP4601667A1 (en) | 2022-10-10 | 2025-08-20 | Therapeutics by Design, LLC | Tissue differentiation factor related polypeptides (tdfrps) for the treatment of myocardial injury |
| CN117653714A (zh) * | 2023-03-22 | 2024-03-08 | 宁夏医科大学 | AAV9-HGF联合TGF-β-Smad受体抑制剂SB431542在治疗矽肺纤维化中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE493141T1 (de) * | 1996-03-22 | 2011-01-15 | Stryker Corp | Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns |
| EP1572950B1 (en) * | 2002-06-17 | 2012-10-10 | Thrasos, Inc. | Single domain tdf-related compounds and analogs thereof |
| EP2789342A1 (en) * | 2004-06-17 | 2014-10-15 | Thrasos Innovation, Inc. | TDF-related compounds and analogs thereof |
| US8299212B2 (en) * | 2005-09-20 | 2012-10-30 | Thrasos Therapeutics, Inc. | TDF-related compounds and analogs thereof, analogs and bioactive fragments |
| US20110275574A1 (en) * | 2009-01-16 | 2011-11-10 | Agency For Science, Technology And Research | Method of inhibiting proliferation of hepatic stellate cells |
| US8642834B2 (en) * | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010128158A1 (en) * | 2009-05-08 | 2010-11-11 | Novartis Ag | Diagnostic biomarkers for fibrotic disorders |
-
2012
- 2012-07-19 WO PCT/US2012/047468 patent/WO2013013085A2/en not_active Ceased
- 2012-07-19 CN CN201610543024.0A patent/CN106478776A/zh active Pending
- 2012-07-19 HK HK14111848.5A patent/HK1198333A1/zh unknown
- 2012-07-19 CN CN201280045650.7A patent/CN103890003B/zh not_active Expired - Fee Related
- 2012-07-19 US US13/553,685 patent/US20140057831A1/en not_active Abandoned
- 2012-07-19 CA CA2842330A patent/CA2842330A1/en not_active Abandoned
- 2012-07-19 BR BR112014001268A patent/BR112014001268A2/pt not_active IP Right Cessation
- 2012-07-19 JP JP2014521801A patent/JP2014527040A/ja active Pending
- 2012-07-19 RU RU2014105513/04A patent/RU2014105513A/ru not_active Application Discontinuation
- 2012-07-19 AU AU2012283924A patent/AU2012283924A1/en not_active Abandoned
- 2012-07-19 EP EP12814119.9A patent/EP2734220A4/en not_active Withdrawn
-
2014
- 2014-01-16 IL IL230510A patent/IL230510A0/en unknown
-
2015
- 2015-08-05 US US14/818,652 patent/US20160058829A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013013085A3 (en) | 2014-03-13 |
| JP2014527040A (ja) | 2014-10-09 |
| US20160058829A1 (en) | 2016-03-03 |
| AU2012283924A1 (en) | 2014-02-06 |
| HK1198333A1 (zh) | 2015-04-02 |
| EP2734220A4 (en) | 2015-01-21 |
| CN103890003A (zh) | 2014-06-25 |
| CN103890003B (zh) | 2016-08-24 |
| CA2842330A1 (en) | 2013-01-24 |
| CN106478776A (zh) | 2017-03-08 |
| US20140057831A1 (en) | 2014-02-27 |
| EP2734220A2 (en) | 2014-05-28 |
| IL230510A0 (en) | 2014-03-31 |
| WO2013013085A2 (en) | 2013-01-24 |
| BR112014001268A2 (pt) | 2017-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527040A5 (enExample) | ||
| AU2018218179B2 (en) | Methods of treating influenza | |
| JP6887987B2 (ja) | Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ | |
| JP2019507781A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| CL2011000353A1 (es) | Compuestos derivados de 1-{4-[metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino]ciclohexil}metanosulfonamida o una sal farmaceuticamente aceptable; forma cristalina de la sal maleato; procedimiento de preparacion; composicion farmaceutica; y uso para tratar enfermedades alergicas, cancer, lupus. | |
| US11684652B2 (en) | HMGB1 antagonist treatment of acute lung injury | |
| BR112014010228A8 (pt) | inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática | |
| JP2023081969A (ja) | Ｔｌｒアゴニストによる呼吸器感染症の治療 | |
| RU2019123160A (ru) | Способ модуляции активности инфламмасом и воспаления в легком | |
| JP2015518818A5 (enExample) | ||
| TW201532606A (zh) | 使用化合物之組合治療ｃ型肝炎病毒感染 | |
| JP2013520405A5 (enExample) | ||
| EP3728289B1 (en) | Optimised compounds | |
| JP2013504589A5 (enExample) | ||
| US20100087447A1 (en) | Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination | |
| SG10201407013QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| JP2012070740A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| EA201201114A1 (ru) | Агонистические dr5-связывающие полипептиды | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| JP2014510082A (ja) | インターロイキン−１受容体のアンタゴニスト | |
| US20130172414A1 (en) | Pharmaceutical composition comprising levocarnitine and dobesilate | |
| JP2018538306A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161128 |